ALK and non-small cell lung carcinoma: Along the lines of the Japanese data, our group from the University of Colorado recently reviewed the outcomes of patients with ALK and EGFR driven NSCLC brain metastases treated with SRS alone for ≥4 lesions (range 4–26) (32).